Vanguard Portfolio Management’s Castle Biosciences CSTL Stock Holding History
Bought
Maintained
Sold
Other funds holding CSTL
Vanguard Portfolio Management's CSTL Position: Q3 2026 in Review
Vanguard Portfolio Management reduced its Castle Biosciences (CSTL) stake by 15% in Q3 2026, selling an estimated $3.75M and leaving 716,665 shares worth $25.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1880.
Vanguard Portfolio Management first reported a position in CSTL in Q1 2026 and has held it in 3 quarters since. 202 funds tracked by Wall St. Rank hold CSTL as of Q3 2026.
- Vanguard Portfolio Management held 716,665 shares of Castle Biosciences worth $25.5M as of Q3 2026.
- Vanguard Portfolio Management sold 124,120 Castle Biosciences shares in Q3 2026, an estimated $3.75M.
- Castle Biosciences made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q3 2026, its #1880 holding.
- Vanguard Portfolio Management first reported a position in Castle Biosciences in Q1 2026 and has held it in 3 quarters since.
- 202 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2026.
Based on Vanguard Portfolio Management's 13F filing for Q3 2026, filed 13 Nov 2026.